CTRI/2023/01/048645招募中3 期
Multicenter, Randomized, Open-label, Comparative, Parallel Group study to assess the efficacy and safety of a fixed dose combination of Lupins Glycopyrronium plus Vilanterol dry powder inhaler versus fixed dose combination of Glycopyrronium plus Formoterol dry powder inhaler in patients with Chronic obstructive pulmonary disease
upin Limited0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Male or female patients, aged >=18 to <= 75 years at screening
- •2. Patients with a diagnosis of COPD (as defined by the GOLD Guidelines, 2021)
- •3. Post-bronchodilator FEV1 >=30% and <80% of the predicted normal value and post-bronchodilator FEV1/FVC (forced vital capacity) ratio < 0.70
- •4. A modified Medical Research Council dyspnoea scale (mMRC) grade 2 or greater.
- •5. COPD treatment stable dose of maintenance monotherapy (LAMA, LABA or ICS), or stable dose of double maintenance therapy (LAMA/LABA or ICS/LABA), for one month prior to screening
- •6. Current or previous cigarette/beedi smokers with a history of cigarette/beedi smoking of at least 10 pack/years. (Previous smokers are defined as those who have stopped smoking for at least 6 months prior to Screening Visit.)
排除标准
- •Subjects who will not meet any of the following criteria will be included in the trial:
- •1. Patients who are currently receiving dual drug treatment with LABA+LAMA
- •2. Known respiratory disorders other than COPD including, but not limited to the following: tuberculosis, alpha-1 antitrypsin deficiency, cystic fibrosis, asthma, active bronchiectasis, sarcoidosis, lung fibrosis, pulmonary hypertension, pulmonary edema, or interstitial lung disease
- •3. Evidence or history of other clinically significant cardiovascular disease or abnormality (such as, but not limited to, congestive heart failure, uncontrolled hypertension, uncontrolled coronary artery disease, myocardial infarction, arrhythmia, long QT syndrome, atrial fibrillation), renal, neurological, endocrine, immunological, psychiatric, hepatic, or hematological disease or abnormality which, in the opinion of the investigator, are clinically significant and would put the patient at risk through study participation, or would affect the study analyses if the disease exacerbates during the study
- •4. No significant abnormality that suggests chest disease other than COPD, on chest X-ray or computed tomography (CT) scan taken within six months before screening. If there is no chest X-ray/CT scan is taken within six months prior to screening, a chest X-ray will be performed during screening to rule out any other significant abnormality.
- •5. History of paradoxical bronchospasm, narrow-angle glaucoma, prostatic hyperplasia, bladder neck obstruction, or severe renal impairment or urinary retention or any other condition, which, in the opinion of the investigator, would contraindicate the use of an anticholinergic or long-acting beta-agonist agent
- •6. History of allergy or hypersensitivity to any of the ingredients of study drugs or components of the delivery system
- •7. Suspected or confirmed SARS-COV2 infection at screening (prior to randomization the subjects will be tested for COVID 19 through rapid antigen test).
- •8.Hospitalization for COPD exacerbation or pneumonia within three months prior to screening. Any subject who experiences pneumonia and/or moderate or severe COPD exacerbation during the run-in period will be excluded.
- •9. Clinically significant abnormal electrocardiogram (ECG) finding at screening.
- •10. Lung volume reduction surgery within 12 months prior to the initiation of the study.
- •11. Requirement of long term ( > 12 hours daily) oxygen therapy
- •12. Unable to stop the following medications at the defined times prior to screening spirometry:
- •Medication Required washout period prior to screening spirometry
- •Ipratropium or ipratropium/salbutamol 8 Hrs
- •combination product
- •Inhaled short acting β-agonists 6 hours
- •Oral β 2-agonists 48 hours
- •Long acting β-agonists
- •(salmeterol and formoterol)
- •or ICS/LABA combination products 48 hours
- •Xanthines 48 hours
- •Cromolyn and nedocromil inhalers 24 hours
- •Zafirlukast, montelukast, zileuton 48 hours
- •Long-acting anticholinergics
- •(Tiotropium etc.) 48 hours
- •Oral or parenteral corticosteroids 6 weeks
- •Any other investigational medication 30 day
研究者
相似试验
已完成
3 期
A Clinical study to compare the effictiveness and safety of Forb 100 HFA aerosol for inhalation and Foradil Combi set of capsules with inhalation powder in patients with Asthma.CTRI/2017/05/008531RUS Biopharm LLC116
尚未招募
3 期
Comparative Study of the Efficacy and Safety of Budesonide, Inhalation Powder, Capsule 400 μg/doseCTRI/2017/02/007787Rus Biopharm LLC136
已完成
4 期
Open-label, multicenter, uncontrolled, randomized, post market clinical follow-up (PMCF) study to confirm effectiveness and safety of Belotero® Revive in facial skin revitalization and photo-damaged skin treatmentDRKS00025699Merz Pharmaceuticals GmbH159
已完成
不适用
Open label, comparative, randomised, multicentre study of trastuzumab given with docetaxel versus sequential single agent therapy with trastuzumab followed by docetaxel as first-line treatment for Her2neu+++ metastatic breast cancer patientsMalignant neoplasm of the breastBreast cancerCancerISRCTN13770586Breast Cancer Study Group (BOOG) (The Netherlands)100
进行中（未招募）
不适用
on-blinded phase II study to compare the efficacy and safety of CetuGEX™ plus chemotherapy with cetuximab plus chemotherapy for the treatment of patients with stage III/IV recurrent and/or metastatic squamous cell carcinoma of the head and neckstage III/IV recurrent and/or metastatic squamous cell carcinoma of the head and neckMedDRA version: 14.1Level: PTClassification code 10060121Term: Squamous cell carcinoma of head and neckSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-003695-13-ITGlycotope GmbH240